Cecilia A. Castellano
A5028924386- COVID-19 and healthcare impacts
- COVID-19 Clinical Research Studies
- Acute Myeloid Leukemia Research
- Economic and Financial Impacts of Cancer
- Epigenetics and DNA Methylation
- Global Cancer Incidence and Screening
- Cancer Genomics and Diagnostics
- Tracheal and airway disorders
- Healthcare cost, quality, practices
- Cancer Immunotherapy and Biomarkers
- Esophageal and GI Pathology
- Infection Control and Ventilation
- Effects of Radiation Exposure
- Immune Cell Function and Interaction
- Autoimmune and Inflammatory Disorders Research
- Chronic Disease Management Strategies
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Vascular Anomalies and Treatments
- Venous Thromboembolism Diagnosis and Management
- Bone and Joint Diseases
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- DNA Repair Mechanisms
- Eosinophilic Disorders and Syndromes
- Parvovirus B19 Infection Studies
- Foreign Body Medical Cases
Emory University
2022-2024
Research Institute Hospital 12 de Octubre
2024
Hospital Universitario 12 De Octubre
2024
Universidad Complutense de Madrid
2024
Cancer Institute (WIA)
2023
Broad Institute
2021
Harvard University
2021
Dana-Farber Cancer Institute
2020-2021
Massachusetts Institute of Technology
2021
Brigham and Women's Hospital
2017-2018
Thrombosis in myeloproliferative neoplasms is associated with increased NETosis that can be targeted JAK inhibitors.
Importance Cytokine storm due to COVID-19 can cause high morbidity and mortality may be more common in patients with cancer treated immunotherapy (IO) immune system activation. Objective To determine the association of baseline immunosuppression and/or IO-based therapies severity cytokine cancer. Design, Setting, Participants This registry-based retrospective cohort study included 12 046 reported Cancer Consortium (CCC19) registry from March 2020 May 2022. The CCC19 is a centralized...
Clonal hematopoiesis results from somatic mutations in cancer driver genes hematopoietic stem cells. We sought to identify novel drivers of clonal expansion using an unbiased analysis sequencing data 84,683 persons and identified common the 5-methylcytosine reader,
Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether COVID-19 increased by anticancer therapy, uncertain. Using data derived from the Cancer Consortium (CCC19), we show that patients treated for an compared control populations non-B-lymphoid malignancies. Among malignancies, those who received therapy within 12 months...
Abstract Introduction COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated severity among melanoma, assessing outcomes of on active targeted or immune therapy. Methods Using the and Cancer Consortium (CCC19) registry, identified 307 diagnosed COVID-19. We used multivariable models assess demographic, cancer-related, treatment-related a...
Background: Limited information is available for patients with breast cancer (BC) and coronavirus disease 2019 (COVID-19), especially among underrepresented racial/ethnic populations. Methods: This a COVID-19 Cancer Consortium (CCC19) registry-based retrospective cohort study of females active or history BC laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection diagnosed between March 2020 June 2021 in the US. Primary outcome was severity measured on...
Abstract Background COVID‐19 can have a particularly detrimental effect on patients with cancer, but no studies to date examined if the presence, or site, of metastatic cancer is related outcomes. Methods Using and Cancer Consortium (CCC19) registry, authors identified 10,065 (2325 7740 without metastasis at time diagnosis). The primary ordinal outcome was severity: not hospitalized, hospitalized did receive supplemental O 2 , received admitted an intensive care unit, mechanical ventilation,...
Introduction The aims of this study were to update our experience with biodegradable polydioxanone (PDO) airway stents in children focusing on effectiveness and safety, analyse the factors involved different outcomes observed. Materials methods Retrospective patients managed PDO from 2012 2023. Variables collected: demographics, comorbidities, indication , clinical baseline, stent size, location, complications, outcome, time follow-up. Statistical analyses performed order detect eventual...
Abstract Introduction The aims of this study were to update our experience with biodegradable polydioxanone (PDO) airway stents in children, focusing on effectiveness and safety, analyze the factors involved different outcomes observed. Materials Methods Retrospective patients managed PDO from 2012 2023. Variables collected: demographics, comorbidities, indication, clinical baseline, stent size, location, complications, outcome, time follow‐up. Statistical analyses performed detect eventual...
Data regarding outcomes among patients with cancer and co-morbid cardiovascular disease (CVD)/cardiovascular risk factors (CVRF) after SARS-CoV-2 infection are limited. To compare Coronavirus 2019 (COVID-19) related complications without CVD/CVRF. Retrospective cohort study of laboratory-confirmed SARS-CoV-2, reported to the COVID-19 Cancer Consortium (CCC19) registry from 03/17/2020 12/31/2021. CVD/CVRF was defined as established CVD or no CVD, male ≥ 55 female 60 years, one additional...
e18790 Background: Patients with SARS-CoV-2 a diagnosis of cancer have increased risk severe COVID-19 outcomes compared to patients without cancer. However, little is known regarding and in the setting human immunodeficiency virus (HIV). Given unique risks this population, we sought understand using registry data. Methods: This descriptive research study utilizing CCC19 registry, an international multi-institutional healthcare provider-reported cases COVID-19. Between March 2020-December...
ABSTRACT Background Limited information is available for patients with breast cancer (BC) and coronavirus disease 2019 (COVID-19), especially among underrepresented racial/ethnic populations. Methods This a COVID-19 Cancer Consortium (CCC19) registry-based retrospective cohort study of females active or history BC laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection diagnosed between March 2020 June 2021 in the US. Primary outcome was severity measured...
<div>Abstract<p>Clonal hematopoiesis results from somatic mutations in cancer driver genes hematopoietic stem cells. We sought to identify novel drivers of clonal expansion using an unbiased analysis sequencing data 84,683 persons and identified common the 5-methylcytosine reader <i>ZBTB33</i> as well <i>YLPM1, SRCAP</i>, <i>ZNF318</i>. also these at low frequency patients with myelodysplastic syndrome. <i>Zbtb33</i>-edited mouse...
<div>Abstract<p>Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether COVID-19 increased by anticancer therapy, uncertain. Using data derived from the Cancer Consortium (CCC19), we show that patients treated for an compared control populations non–B-lymphoid malignancies. Among malignancies, those who received...
<div>Abstract<p>Clonal hematopoiesis results from somatic mutations in cancer driver genes hematopoietic stem cells. We sought to identify novel drivers of clonal expansion using an unbiased analysis sequencing data 84,683 persons and identified common the 5-methylcytosine reader <i>ZBTB33</i> as well <i>YLPM1, SRCAP</i>, <i>ZNF318</i>. also these at low frequency patients with myelodysplastic syndrome. <i>Zbtb33</i>-edited mouse...
<div>Abstract<p>Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether COVID-19 increased by anticancer therapy, uncertain. Using data derived from the Cancer Consortium (CCC19), we show that patients treated for an compared control populations non–B-lymphoid malignancies. Among malignancies, those who received...
<p>Supplementary Figures S1-S11</p>
Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
<p>Supplementary Figures S1-S11</p>
Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19